Biotech Values

[DewDiligence]

Addendum re Roche's potential share buyback: In a sense, the pharma business is becoming more like the banking business. The future profit margins in pharma will almost certainly be lower than they have been during the past few decades, and hence leveraging the balance sheet will be necessary to maintain a robust return on equity.